Participate in a Study

Current Studies

Cardiac Trials

Study – EX4758

• eGFR ≥15 and < 60 mL/min/1.73 m2
• Serum hs-CRP ≥2 mg/L at screening
• Evidence of ASCVD by one or more of the following within the last 5 years from screening:
  • Coronary heart disease defined as at least one of the following:
  • Cerebrovascular disease defined as at least one of the following:
  • Symptomatic peripheral artery disease (PAD) defined as at least one of the following:

Type 2 Diabetes Trials:

Study – CIP341

• Is age 18 - 80 years at time of screening.
• Has a clinical diagnosis of type 2 diabetes for 2 years or more.
• Is on multiple daily injection (MDI) regimen (basal/bolus regimen with longacting insulin and rapid-acting analogs), defined as greater than or equal to 2 injections per day for at least 3 months.
• Is willing to perform fingerstick blood glucose measurements as needed.
• Is willing to wear the system continuously throughout the study.
• Has a Glycosylated hemoglobin (HbA1c) of less than 10% (as processed by Central Lab) at time of screening visit.
• Is willing to upload data from the study pump, must have Internet access, and a computer system, or compatible smartphone that meets the requirements for uploading the study pump.

Type 1 or 2 Diabetes Trials:

Study – CIP322

• Individual is 2-75 years of age at time of enrollment.
• Subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
• Subject is using insulin to treat their diabetes.
• Subject agrees to comply with the study protocol requirements.
• Subject is willing to perform SMBG approximately every 15 minutes /20 minutes during FST.
• If subject is participating in YSI FST, subject has adequate venous access as assessed by investigator or appropriate staff.